title: Modes of action of Leishmanicidal antimicrobial peptides.
abstract: Leishmaniasis is one of the major neglected tropical diseases of the world. It is present in 88 countries with an estimated number of 500,000 cases of visceral leishmaniasis and 1.5 million cases of cutaneous disease. No effective vaccinations are available against leishmaniasis and the efficacy of existing treatments is compromised due to the emergence of drug resistance. Thus, there is an urgent need to develop new compounds with antileishmanial activity. Antimicrobial peptides have potential as novel antileishmanial therapy, either for use alone or in combination with current drug regimens. The modes of action of these peptides against Leishmania includes: membrane disruption leading to necrotic cell death; induction of apoptosis; binding to intracellular target(s); and indirect effects via immunomodulation of host immune cells. This article reviews the mechanisms of action of antimicrobial peptides with leishmanicidal activity.
authors.affiliation: Immunity & Infection Research Centre, Vancouver Coastal Health Research Institute, Vancouver, BC, Canada.
authors.forename: Alexandra K
authors.initials: AK
authors.lastname: Marr
authors.forename: Bradford S
authors.initials: BS
authors.lastname: McGwire
authors.forename: W Robert
authors.initials: WR
authors.lastname: McMaster
mesh_terms: D000818:Animals; D023181:Antimicrobial Cationic Peptides / Q000737:chemistry / Q000494:pharmacology*; D000981:Antiprotozoal Agents / Q000737:chemistry / Q000494:pharmacology*; D017209:Apoptosis; D002462:Cell Membrane / Q000187:drug effects; D006801:Humans; D056747:Immunomodulation; D007891:Leishmania / Q000187:drug effects*; D007896:Leishmaniasis / Q000188:drug therapy / Q000276:immunology / Q000469:parasitology
chemical_list: D023181:Antimicrobial Cationic Peptides; D000981:Antiprotozoal Agents